Trial Profile
Phase I Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2017
Price :
$35
*
At a glance
- Drugs Tivanisiran (Primary)
- Indications Dry eyes; Ocular pain
- Focus Adverse reactions
- Sponsors Sylentis
- 11 Jun 2014 New trial record